UNSPSC 51373459: Codeine/pseudoephedrine/triprolidine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373459 Codeine/pseudoephedrine/triprolidine is a Commodity code that in recent state and local procurement activity designates pharmaceutical products including naloxone, over-the-counter medications, and generic multi-source drugs for distribution through public health and government facilities. State and local buyers under this code include county health departments and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the issuing bodies in the recent opportunities block — the former a single county health department, the latter an alliance of state and local government facilities across Minnesota and Oregon. The scope of work reflects pharmaceutical procurement at scale: Seminole County sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, while MMCAP issued an RFP to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC).

Recent activity concentrates in the upper Midwest and Southeast. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, with a response deadline of July 26, 2023 (note: the posted date and response deadline do not align in the source), requiring quarterly deliveries to the Seminole County Community Health Building in Sanford. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, posted RFP S1070000015802 on January 20, 2026, with proposals due March 26, 2026; the contract term runs two years from July 1, 2026, with optional extensions at MMCAP's discretion. Both solicitations require vendors to submit detailed product information including NDC codes and pricing, comply with FDA requirements and cGMP certification, and maintain specified insurance coverage. MMCAP evaluates proposals weighted heavily on price competitiveness (75 percent) and reserves the right to make sole, dual, or multi-awards based on therapeutic considerations and member needs. Neither solicitation identifies explicit set-aside designations for disadvantaged enterprises.